1. Home
  2. VTYX vs SUNS Comparison

VTYX vs SUNS Comparison

Compare VTYX & SUNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTYX
  • SUNS
  • Stock Information
  • Founded
  • VTYX 2018
  • SUNS 2023
  • Country
  • VTYX United States
  • SUNS United States
  • Employees
  • VTYX N/A
  • SUNS N/A
  • Industry
  • VTYX Medicinal Chemicals and Botanical Products
  • SUNS Real Estate Investment Trusts
  • Sector
  • VTYX Health Care
  • SUNS Real Estate
  • Exchange
  • VTYX Nasdaq
  • SUNS Nasdaq
  • Market Cap
  • VTYX 154.9M
  • SUNS 130.5M
  • IPO Year
  • VTYX 2021
  • SUNS N/A
  • Fundamental
  • Price
  • VTYX $8.09
  • SUNS $9.42
  • Analyst Decision
  • VTYX Buy
  • SUNS Strong Buy
  • Analyst Count
  • VTYX 3
  • SUNS 3
  • Target Price
  • VTYX $12.50
  • SUNS $13.58
  • AVG Volume (30 Days)
  • VTYX 9.8M
  • SUNS 53.1K
  • Earning Date
  • VTYX 11-06-2025
  • SUNS 11-13-2025
  • Dividend Yield
  • VTYX N/A
  • SUNS 12.66%
  • EPS Growth
  • VTYX N/A
  • SUNS N/A
  • EPS
  • VTYX N/A
  • SUNS 1.04
  • Revenue
  • VTYX N/A
  • SUNS $16,359,932.00
  • Revenue This Year
  • VTYX N/A
  • SUNS $183.25
  • Revenue Next Year
  • VTYX N/A
  • SUNS $62.46
  • P/E Ratio
  • VTYX N/A
  • SUNS $9.09
  • Revenue Growth
  • VTYX N/A
  • SUNS 1342.10
  • 52 Week Low
  • VTYX $0.78
  • SUNS $7.80
  • 52 Week High
  • VTYX $9.50
  • SUNS $15.74
  • Technical
  • Relative Strength Index (RSI)
  • VTYX 76.14
  • SUNS 39.99
  • Support Level
  • VTYX $5.75
  • SUNS $9.42
  • Resistance Level
  • VTYX $9.50
  • SUNS $9.91
  • Average True Range (ATR)
  • VTYX 0.78
  • SUNS 0.36
  • MACD
  • VTYX 0.33
  • SUNS 0.01
  • Stochastic Oscillator
  • VTYX 76.85
  • SUNS 13.62

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

About SUNS Sunrise Realty Trust Inc. Common Stock

Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.

Share on Social Networks: